Nutra Pharma Corp (NPHC) Cash from Financing Activities (2010 - 2026)

Nutra Pharma has disclosed Cash from Financing Activities across 17 years of filings, most recently posting $229379.0 for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 39.41% year-over-year to $229379.0; the TTM figure through Jun 2026 stood at $970533.0 (up 3.21% YoY), while the FY2025 annual figure was $1.2 million, up 184.12% from the prior year.
• Cash from Financing Activities came in at $229379.0 for Q2 2026 at Nutra Pharma, down from $337454.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $408454.0 in Q1 2025 to a low of -$53073.0 in Q3 2024.
• Average Cash from Financing Activities over 5 years is $180754.8, with a median of $185977.5 recorded in 2023.
• Year-over-year, Cash from Financing Activities soared 3951.34% in 2023 and tumbled 204.73% in 2024.
• Over 5 years, Cash from Financing Activities stood at $2532.0 in 2022, then soared by 3951.34% to $102580.0 in 2023, then soared by 101.17% to $206357.0 in 2024, then advanced by 10.68% to $228396.0 in 2025, then climbed by 0.43% to $229379.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $229379.0 in Q2 2026, $337454.0 in Q1 2026, and $228396.0 in Q4 2025.